Browse by Authors and Editors
Number of items: 3. 2017Middleton, Gary and Palmer, Daniel H. and Greenhalf, William and Ghaneh, Paula and Jackson, Richard and Cox, Trevor and Evans, Anthony and Shaw, Victoria E. and Wadsley, Jonathan and Valle, Juan W. and Propper, David and Wasan, Harpreet and Falk, Stephen and Cunningham, David and Coxon, Fareeda and Ross, Paul and Madhusudan, Srinivasan and Wadd, Nick and Corrie, Pippa and Hickish, Tamas and Costello, Eithne and Campbell, Fiona and Rawcliffe, Charlotte and Neoptolemos, John P. (2017) Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, 18 (4). pp. 486-499. ISSN 1474-5488 2014Middleton, Gary and Silcocks, Paul and Cox, Trevor and Valle, Juan and Wadsley, Jonathan and Propper, David and Coxon, Fareeda and Ross, Paul and Srinivasan, Madhusudan and Roques, Tom and Cunningham, David and Falk, Stephen and Wadd, Nick and Harrison, Mark and Corrie, Pippa and Iveson, Tim and Robinson, Angus and McAdam, Karen and Eatock, Martin and Evans, Jeff and Archer, Caroline and Hickish, Tamas and Garcia-Alonso, Angel and Nicolson, Marianne and Steward, William and Anthoney, D. Alan and Greenhalf, William and Shaw, Victoria E. and Costello, Eithne and Naisbitt, Dean and Rawcliffe, Charlotte and Nanson, Gemma and Neoptolemos, John P. (2014) Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, 15 (8). pp. 829-840. ISSN 1474-5488 Ford, Hugo and Marshall, Andrea and Bridgewater, John A. and Janowitz, Tobias and Coxon, Fareeda and Wadsley, Jonathan and Mansoor, Wasat and Fyfe, David and Madhusudan, Srinivasan and Middleton, Gary and Swinson, Daniel and Falk, Stephen and Chau, Ian and Cunningham, David and Kareclas, Paula and Cook, Natalie and Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology, 15 (1). pp. 78-86. ISSN 1474-5488 |
